Injective: Why INJ’s 5% pullback may not spell trouble IF…

Injective [INJ] spent most of the past year trapped in a prolonged downtrend after collapsing from above $18 to a low near $2.61. However, selling pressure gradually faded as buyers absorbed supply around the bottom, allowing a recovery structure to form. As accumulation strengthened, INJ pushed through the critical $6.29 barrier and briefly rallied to $7.14, supported by rising volume and improving market participation. That breakout signaled growing confidence among traders because $6.29 had repeatedly rejected previous recovery attempts. Nevertheless, recent candles revealed hesitation as Short-Term Holders (STH) lock in profits while Bitcoin [BTC] entered a corrective phase. This explains why INJ pulled back 5% despite maintaining a bullish structure. Even so, the RSI remained near 69 at press time, showing momentum still favors buyers rather than a complete trend reversal failure. Therefore, the market now faces a key test. If buyers defend $6.29 during the retest, it would confirm that former resistance has flipped into support. Such behavior would suggest continued accumulation and could open a path toward $7.80 and eventually $8.90. However, losing $6.29 would imply breakout buyers are losing conviction. In that case, INJ could revisit the $5.80-$6.00 demand zone as broader market caution and Bitcoin weakness encourage further profit-taking. Capital inflows support INJ's breakout The breakout above $6.29 attracted more than price momentum. Trading volume declined by 12.8%, sitting at $220 million over the past 24 hours of press time. The elevated trading volume highlights strong market participation amid the ongoing breakout and pullback phase. The underlying network also strengthened. At the time of writing, Injective's TVL hovered around $12.81 million, rising by 7.82% in the last day. This suggested that capital continued entering the ecosystem despite the retracement. This alignment points to growing engagement across both trading and on-chain activity. Still, the move faces an important test. Sustained growth in volume and TVL would support continuation, while slowing participation could weaken momentum. Can buyers hold the $6.40 breakout zone? Injective's latest pullback reflects a market transitioning from expansion into consolidation. Buyers previously overwhelmed sellers near $6.40, triggering a breakout that carried INJ above $7.00 and eventually to $7.35. As momentum peaked, early participants began securing profits, which explains the sharp rejection from resistance and the return toward $6.59. However, the decline has not disrupted the broader structure. Instead, it suggests the market is seeking equilibrium after a nearly 27% rally from $5.80. Such pauses often occur when strong price moves absorb nearby liquidity and require fresh demand before extending higher. Focus now shifts to the $6.80-$6.40 region. If buyers absorb selling pressure there, it would signal confidence remains intact despite recent volatility. That could support another test of $7.35 and potentially pave the way toward $8.00. Failure to hold $6.40 would weaken bullish momentum and increase the risk of a deeper retracement toward the $6.00-$6.20 demand zone. Final Summary Injective sustained strong capital inflows, with rising volume and TVL reinforcing the breakout's underlying strength. Injective remains bullish above $6.40, while a successful retest could reopen the path toward $7.35-$8.00.